Phentolamine mesylate injectable - Novalar Pharmaceuticals

Drug Profile

Phentolamine mesylate injectable - Novalar Pharmaceuticals

Alternative Names: NV-101; OraVerse

Latest Information Update: 09 Sep 2015

Price : $50

At a glance

  • Originator Repros Therapeutics
  • Developer Novalar Pharmaceuticals; Sanofi; Septodont
  • Class Erectile dysfunction therapies; Imidazoles; Peripheral vasodilators; Small molecules
  • Mechanism of Action Alpha adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaesthesia

Most Recent Events

  • 09 Sep 2015 Phentolamine mesylate injectable is still in Preregistration in France, Spain and Italy
  • 18 Mar 2011 Novalar and Septodont enter into an agreement whereby Septodont acquires phentolamine mesylate for North America and unpartnered international markets
  • 14 Jul 2010 Preregistration for Anaesthesia in Spain (Submucosal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top